1. Home
  2. VLY vs ERAS Comparison

VLY vs ERAS Comparison

Compare VLY & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valley National Bancorp

VLY

Valley National Bancorp

N/A

Current Price

$14.14

Market Cap

7.8B

Sector

Finance

ML Signal

N/A

Logo Erasca Inc.

ERAS

Erasca Inc.

N/A

Current Price

$14.34

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VLY
ERAS
Founded
1927
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8B
6.3B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
VLY
ERAS
Price
$14.14
$14.34
Analyst Decision
Buy
Buy
Analyst Count
14
9
Target Price
$16.89
★ $24.11
AVG Volume (30 Days)
★ 6.8M
4.9M
Earning Date
10-22-2026
11-11-2026
Dividend Yield
★ 3.08%
N/A
EPS Growth
★ 46.38
36.23
EPS
★ 0.57
N/A
Revenue
N/A
N/A
Revenue This Year
$12.61
N/A
Revenue Next Year
$20.48
N/A
P/E Ratio
$25.01
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.34
$2.11
52 Week High
$15.20
$24.28

Technical Indicators

Market Signals
Indicator
VLY
ERAS
Relative Strength Index (RSI) 66.03 44.01
Support Level $13.32 $13.47
Resistance Level $15.00 $15.03
Average True Range (ATR) 0.31 0.96
MACD 0.19 0.09
Stochastic Oscillator 88.26 43.75

Price Performance

Historical Comparison
VLY
ERAS

About VLY Valley National Bancorp

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: